Mega Genomics (HKSE:06667) Current Accrued Expense : HK$0.0 Mil (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Mega Genomics Current Accrued Expense?

Mega Genomics's Current Accrued Expense for the quarter that ended in Jun. 2024 was HK$0.0 Mil.

Mega Genomics Current Accrued Expense Historical Data

The historical data trend for Mega Genomics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Genomics Current Accrued Expense Chart

Mega Genomics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Mega Genomics Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Current Accrued Expense	Get a 7-Day Free Trial				-	-	-	-	-

Mega Genomics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Mega Genomics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Mega Genomics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Mega Genomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mega Genomics Ltd (HKSE:06667) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

North Garden Road, 401 Health Work, Haidian District, Beijing, CHN

Website

https://www.megagenomics.cn

Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening, and infectious disease diagnosis, to meet consumers growing preventive medical needs. It generates a majority of its revenue from consumer genetic testing services.

Executives

Dongyin Industrial (shenzhen) Co., Ltd.	2106 Person having a security interest in shares
Dongyin (tianjin) Enterprise Management Consulting Co., Ltd.	2106 Person having a security interest in shares
Dongfu Hetong (tianjin) Equity Investment Fund Partnership Enterprise (limited Partnership)	2106 Person having a security interest in shares
Yurong Technology Limited	2101 Beneficial owner
Dongfu (beijing) Investment Management Co., Ltd.	2106 Person having a security interest in shares
Dong Yin Development (holdings) Limited	2106 Person having a security interest in shares
China Orient Asset Management Co., Ltd.	2106 Person having a security interest in shares
Beijing Dongfu Huitong Investment Management Center (limited Partnership)	2106 Person having a security interest in shares
Guo Meiling	2101 Beneficial owner
Yu Rong	2501 Other
Lin Lin	2101 Beneficial owner
Infinite Galaxy Health Limited	2101 Beneficial owner
Bei Jing He He Heng Ye Ke Ji You Xian Gong Si	2201 Interest of corporation controlled by you
Tian Jin Shi Ji Yu Neng Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Bei Jing Shi Ji Yu Neng Ke Ji You Xian Gong Si	2501 Other

Mega Genomics Headlines

No Headlines